Karatzetzou Stella, Tsiptsios Dimitrios, Sousanidou Anastasia, Fotiadou Styliani, Christidi Foteini, Kokkotis Christos, Gkantzios Aimilios, Stefas Eleftherios, Vlotinou Pinelopi, Kaltsatou Antonia, Aggelousis Nikolaos, Vadikolias Konstantinos
Neurology Department, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Department of Physical Education and Sport Science, Democritus University of Thrace, 69100 Komotini, Greece.
Neurol Int. 2023 Jan 16;15(1):83-99. doi: 10.3390/neurolint15010008.
Predicting functional outcome following stroke is considered to be of key importance in an attempt to optimize overall stroke care. Although clinical prognostic tools have been widely implemented, optimal blood biomarkers might be able to yield additional information regarding each stroke survivor's propensity for recovery. Copeptin seems to have interesting prognostic potential poststroke. The present review aims to explore the prognostic significance of copeptin in stroke patients. Literature research of two databases (MEDLINE and Scopus) was conducted to trace all relevant studies published between 16 February 2012 and 16 February 2022 that focused on the utility of copeptin as a prognostic marker in acute stroke setting. 25 studies have been identified and included in the present review. The predictive ability of copeptin regarding both functional outcome and mortality appears to be in the range of established clinical variables, thus highlighting the added value of copeptin evaluation in stroke management. Apart from acute ischemic stroke, the discriminatory accuracy of the biomarker was also demonstrated among patients with transient ischemic attack, intracerebral hemorrhage, and subarachnoid hemorrhage. Overall, copeptin represents a powerful prognostic tool, the clinical implementation of which is expected to significantly facilitate the individualized management of stroke patients.
预测中风后的功能结局被认为对于优化整体中风护理至关重要。尽管临床预后工具已被广泛应用，但理想的血液生物标志物或许能够提供有关每位中风幸存者恢复倾向的更多信息。 copeptin似乎在中风后具有有趣的预后潜力。本综述旨在探讨copeptin在中风患者中的预后意义。对两个数据库（MEDLINE和Scopus）进行了文献研究，以追踪2012年2月16日至2022年2月16日期间发表的所有相关研究，这些研究聚焦于copeptin作为急性中风环境中预后标志物的效用。已确定25项研究并纳入本综述。copeptin对功能结局和死亡率的预测能力似乎与既定临床变量的范围相当，从而凸显了copeptin评估在中风管理中的附加价值。除急性缺血性中风外，该生物标志物在短暂性脑缺血发作、脑出血和蛛网膜下腔出血患者中也显示出判别准确性。总体而言，copeptin是一种强大的预后工具，其临床应用有望显著促进中风患者的个体化管理。
